About Myriad Genetics
Myriad Genetics is a precision medicine company that provides genetic and genomic testing solutions to help patients and healthcare providers make more informed health decisions. The company offers comprehensive testing across five key health areas: hereditary cancer risk assessment, cancer treatment guidance, reproductive health and prenatal care, mental health medication management, and prostate cancer management. Myriad's portfolio includes industry-leading tests such as MyRisk for cancer risk assessment, BRACAnalysis CDx for BRCA mutations, GeneSight for mental health medication guidance, Prequel for non-invasive prenatal testing (NIPT), Prolaris + AI combining genomics with AI-driven digital pathology for prostate cancer, and Precise MRD for minimal residual disease monitoring. The company serves healthcare providers across multiple specialties including oncology, urology, OB/GYN, mental health, and primary care, as well as health systems, biopharma partners, and direct-to-consumer markets. With deep expertise in genetic testing and a commitment to advancing personalized medicine, Myriad Genetics helps unlock the power of genetic information to detect disease early, guide treatment decisions, and prevent disease progression. The company maintains extensive EMR integration capabilities with partners like Epic and Flatiron Health, streamlining test ordering and results delivery within clinical workflows.
Clinical Focus
Medical conditions and clinical areas addressed by Myriad Genetics.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of Prolaris + AI as the first prostate cancer test combining genomics and AI-driven digital pathology for active surveillance management; Partnership with Flatiron Health for OncoEMR integration; Expansion of Epic Aura integration capabilities
Awards & Recognition
Epic Aura founding member; described as offering 'industry-leading genetic insights' and 'best-in-class genetic' testing
Key Partnerships
Social & Media
Latest Updates
Using Prostate Cancer Gene Testing to Guide Treatment Decisions: Insights as We Head into 2026
Myriad Genetics’ continued investment in molecular residual disease (MRD) testing drives new patents granted
Addressing Provider Misconceptions in Ovarian Cancer Genetic Testing
More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment
How Genomic Testing is Transforming Treatment Decisions in Intermediate-Risk Prostate Cancer
Company Details
- Headquarters
- Salt Lake City, UT, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.